The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center ExperienceLorusso D. · Cirillo F. · Mancini M. · Spatti G.B. · Grijuela B. · Ditto A. · Raspagliesi F.
Gynecologic Oncology Unit, Fondazione ‘IRCCS' National Cancer Institute, Milan, Italy
Objectives: The objective of this study was to examine whether the oncologic outcomes of BRCA1-associated and BRCA2-associated ovarian cancers correlate differently. Methods: Genetic data and clinical characteristics were correlated with progression-free survival (PFS) and overall survival (OS). Results: Data from 147 BRCA-mutated patients (119 BRCA1-positive and 28 BRCA2-positive) were analyzed. At a median follow-up of 69 months, the median PFS was 27.2 and 45.46 months for BRCA1 and BRCA2 patients, respectively (p = 0.03). Median OS was 77.23 and 111.47 months for BRCA1 and BRCA2 patients, respectively (p = 0.08). Conclusion:BRCA2 mutations confer PFS and a trend to OS advantage compared with the BRCA1 mutation in BRCA-mutated epithelial ovarian cancer patients.
Gynecologic Oncology Unit
Fondazione IRCCS National Cancer Institute, Milan
Giacomo Venezian 1, IT-20133 Milan (Italy)
Received: April 9, 2013
Accepted after revision: June 10, 2013
Published online: August 13, 2013
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 3, Number of References : 44
Oncology (International Journal for Cancer Research and Treatment)
Vol. 85, No. 2, Year 2013 (Cover Date: August 2013)
Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)
For additional information: http://www.karger.com/OCL